FBRX - Forte Biosciences, Inc.

5.34
-0.540   -10.112%

Share volume: 41,817
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$5.88
-0.54
-0.09%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 0%
Dept financing 10%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-18.84%
1 Month
-9.64%
3 Months
-72.53%
6 Months
6.80%
1 Year
661.77%
2 Year
385.45%
Key data
Stock price
$5.34
P/E Ratio 
0.00
DAY RANGE
$5.02 - $5.88
EPS 
-$6.06
52 WEEK RANGE
$0.28 - $28.68
52 WEEK CHANGE
$640.12
MARKET CAP 
33.201 M
YIELD 
N/A
SHARES OUTSTANDING 
36.504 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
2.30
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$20,155
AVERAGE 30 VOLUME 
$52,782
Company detail
CEO: Paul A. Wagner
Region: US
Website: fortebiorx.com
Employees: 5
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Forte Biosciences is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Recent news
loading